Mitogenic signals initiated via interleukin-6 receptor complexes in cooperation with other transmembrane molecules in myelomas
- PMID: 17142955
- DOI: 10.3960/jslrt.46.55
Mitogenic signals initiated via interleukin-6 receptor complexes in cooperation with other transmembrane molecules in myelomas
Abstract
Cytokines exert multiple biological functions through binding to their specific receptors that triggers activation of intracellular signaling cascades. The cytokine-mediated signals may produce variable and even opposing effects on different cell types, depending on cellular context that is also dictated by the differentiation stage of the cell. Multiple myeloma (MM) is a monoclonal proliferative disorder of human plasma cells. Myeloma cells appear to include mixed subpopulations in accordance with the expression of their surface antigens, such as CD45. Although interleukin-6 (IL-6) is widely accepted as the most relevant growth factor for myeloma cells, only a few subpopulations of tumor cells, such as CD45(+) immature cells, proliferate in response to IL-6. The activation of both signal transducer and activator of transcription (STAT) 3 and extracellular signal-regulated kinase (ERK) 1/2 is not sufficient for IL-6-induced proliferation of myeloma cells that requires the src family kinase activation associated with a rapid translocation of CD45 to lipid rafts. The CD45 expression renders myeloma cells competent for not only mitogenic but also apoptotic stimuli, resulting in either proliferation or apoptosis of CD45(+) myeloma cells dependently upon the circumstantial stimuli. In contrast, in CD45(-) myeloma cells highly expressing IL-6 receptor alpha chain (IL-6Ralpha), IL-6Ralpha and insulin-like growth factor (IGF)-I receptors exist on plasma membrane in close proximity, facilitating efficient assembly of two receptors in response to IL-6. The synergistic effects of IL-6Ralpha on IGF-I receptor-mediated signals provide a novel insight into a Jak-independent IL-6 signaling mechanism of receptor cross talk in human myeloma cells. Furthermore, the signaling cross talk between the cytokine receptor, IL-6Ralpha/gp130 and the growth factor receptor tyrosine kinase, fibroblast growth factor receptor (FGFR) 3 appears in myeloma cells carrying t(4;14)(p16.3;q32). In this review we propose several mechanisms of the IL-6-induced cell proliferation that is strictly dependent upon the cellular context in myelomas.
Similar articles
-
Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules.Int J Hematol. 2003 Aug;78(2):95-105. doi: 10.1007/BF02983376. Int J Hematol. 2003. PMID: 12953802 Review.
-
Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation.Leuk Lymphoma. 2003 Sep;44(9):1477-81. doi: 10.3109/10428190309178767. Leuk Lymphoma. 2003. PMID: 14565647 Review.
-
Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected].Blood. 2004 Mar 15;103(6):2291-8. doi: 10.1182/blood-2003-07-2187. Epub 2003 Oct 30. Blood. 2004. PMID: 14592826
-
Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6.Blood. 2002 Mar 15;99(6):2172-8. doi: 10.1182/blood.v99.6.2172. Blood. 2002. PMID: 11877294
-
Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals.Oncogene. 2005 Sep 15;24(41):6328-32. doi: 10.1038/sj.onc.1208782. Oncogene. 2005. PMID: 15940250
Cited by
-
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol. 2013 Apr;71(4):867-81. doi: 10.1007/s00280-013-2078-0. Epub 2013 Jan 25. Cancer Chemother Pharmacol. 2013. PMID: 23355037 Free PMC article. Clinical Trial.
-
Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases.Neurobiol Dis. 2010 Mar;37(3):549-57. doi: 10.1016/j.nbd.2009.11.013. Epub 2009 Nov 24. Neurobiol Dis. 2010. PMID: 19944161 Free PMC article. Review.
-
The prohibitin protein complex promotes mitochondrial stabilization and cell survival in hematologic malignancies.Oncotarget. 2017 Jul 1;8(39):65445-65456. doi: 10.18632/oncotarget.18920. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029444 Free PMC article.
-
Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.J Pharmacol Exp Ther. 2018 Jun;365(3):734-751. doi: 10.1124/jpet.118.247924. Epub 2018 Apr 9. J Pharmacol Exp Ther. 2018. PMID: 29632237 Free PMC article.
-
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):207-21. doi: 10.1007/s00005-008-0022-5. Epub 2008 May 30. Arch Immunol Ther Exp (Warsz). 2008. PMID: 18512025 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous